Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma

British Journal of Dermatology

Volumn 143, Issue 2, 2000, Pages 269-274

  Jury, C S ^a   Mcallister, E J ^a   Mackie, R M ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Melanoma; S100 protein

Indexed keywords

PROTEIN S 100; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VALIDATION PROCESS;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033849437     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03650.x     Document Type: Article

References (6)

1. Prognostic value of serum analyses of S-100β protein in malignant melanoma
2. Elevated serum levels of S100 and survival in malignant melanoma
3. Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma
4. The luminescence immunoassay S-100: A sensitive test to measure circulating S-100B: Its prognostic value in malignant melanoma
5. Serum S100, a marker for disease monitoring in metastatic melanoma
6. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy